Cronos Group Stock Today
| CRON Stock | CAD 2.94 0.01 0.34% |
Performance0 of 100
| Odds Of DistressOver 66
|
Cronos is selling at 2.94 as of the 28th of November 2024; that is 0.34 percent increase since the beginning of the trading day. The stock's open price was 2.93. Cronos has more than 66 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Cronos Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. The company has 382.3 M outstanding shares of which 4.57 M shares are currently shorted by private and institutional investors with about 51.99 days to cover all short positions. More on Cronos Group
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cronos Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cronos' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cronos or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Michael JD | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
Cronos' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cronos' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsCronos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cronos' financial leverage. It provides some insight into what part of Cronos' total assets is financed by creditors.
| |||||
Cronos Group (CRON) is traded on Toronto Exchange in Canada and employs 356 people. Cronos is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.12 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cronos's market, we take the total number of its shares issued and multiply it by Cronos's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cronos Group operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 382.3 M outstanding shares of which 4.57 M shares are currently shorted by private and institutional investors with about 51.99 days to cover all short positions.
Cronos Group has accumulated about 764.64 M in cash with (42.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cronos Probability Of Bankruptcy
Ownership AllocationCronos holds a total of 382.3 Million outstanding shares. Cronos Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cronos Ownership Details
Cronos Group Risk Profiles
Although Cronos' alpha and beta are two of the key measurements used to evaluate Cronos' performance over the market, the standard measures of volatility play an important role as well.
Cronos Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cronos without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Cronos Corporate Management
Elected by the shareholders, the Cronos' board of directors comprises two types of representatives: Cronos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cronos. The board's role is to monitor Cronos' management team and ensure that shareholders' interests are well served. Cronos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cronos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James III | Controller VP | Profile | |
| Arye Weigensberg | Senior Development | Profile | |
| Shayne Laidlaw | Director Strategy | Profile | |
| James Holm | Chief Officer | Profile | |
| Terry Doucet | General Secretary | Profile | |
| Kevin Gifford | VP Fin | Profile | |
| Anna Shlimak | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.